Healthy subjects
Conditions
Interventions
Sponsors
Miura Clinic, Medical Corporation Kanonkai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Healthy males and females from 20 to 64 years old (2) Male with gamma-GTP level in the range from 61 to 100 IU/L or female with 31 to 65 IU/L, or subjects with ALT and AST level in the range from 31 to 50 IU/L (3) Subjests who recievedd sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing
Exclusion criteria
Exclusion criteria: (1) Subjests with heart, liver, and kidney diseases (including complications of other deseases) (2) Subjests with a history of cardiovascular disease (3) Subjests with diabetes (4) Subjests with diseases currently being treated (5) Subjests who are allergic to food and drugs (6) Subjests with anemia symptoms (7) Female subjects wishing to become pregnant while participating in this study, pregnant (including those who may be pregnant) or lactating gemale subjects (8) Subjests who go to the hospital for some illness or are treated with drugs and Chinese medicine (temporary administration is possible) (9) Subjests who play intense sports and subjects who are on a diet (10) Subjests with extremely irregular eating habits (11) Subjests who may change their lifestyle habits (various daily habits such as diet, exercise, smoking, drinking, and sleeping) during the intake period (12) Subjests who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the test period (13) Subjests who drink more than 60g of avarage daily pure alcohol (14) Subjests who smoke an average of 21 or more cigarettes a day (15) Subjests who are participating in or will participate in other clinica trials at the start of this study (16) Other subjects judged by the investigator or the investigator to be inappropriate for the examination
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function markers | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammation markers Subjective index | — |
Countries
Japan
Contacts
Public ContactMakoto Terashima
Oneness Support Co., Ltd. Clinical Trial Division
Outcome results
None listed